{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:37:20Z","timestamp":1793320640093,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-56537-y","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T11:48:06Z","timestamp":1738928886000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["The anti-PD-L1\/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial"],"prefix":"10.1038","volume":"16","author":[{"given":"Da","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5571-7688","authenticated-orcid":false,"given":"Hongwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kemin","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoluan","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiebing","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaohui","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baocai","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,7]]},"reference":[{"key":"56537_CR1","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1056\/NEJMra1713263","volume":"380","author":"A Villanueva","year":"2019","unstructured":"Villanueva, A. Hepatocellular carcinoma. N. Engl. J. Med. 380, 1450\u20131462 (2019).","journal-title":"N. Engl. J. Med."},{"key":"56537_CR2","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S0140-6736(14)62038-9","volume":"385","author":"C Allemani","year":"2015","unstructured":"Allemani, C. et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 385, 977\u20131010 (2015).","journal-title":"Lancet"},{"key":"56537_CR3","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1001\/jamasurg.2022.7989","volume":"158","author":"ZJ Brown","year":"2023","unstructured":"Brown, Z. J. et al. Management of hepatocellular carcinoma: a review. JAMA Surg. 158, 410\u2013420 (2023).","journal-title":"JAMA Surg."},{"key":"56537_CR4","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.jhep.2023.03.003","volume":"79","author":"L Rimassa","year":"2023","unstructured":"Rimassa, L., Finn, R. S. & Sangro, B. Combination immunotherapy for hepatocellular carcinoma. J. Hepatol. 79, 506\u2013515 (2023).","journal-title":"J. Hepatol."},{"key":"56537_CR5","first-page":"727","volume":"10","author":"Y Han","year":"2020","unstructured":"Han, Y., Liu, D. & Li, L. PD-1\/PD-L1 pathway: current researches in cancer. Am. J. Cancer Res. 10, 727\u2013742 (2020).","journal-title":"Am. J. Cancer Res."},{"key":"56537_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","volume":"50","author":"P Darvin","year":"2018","unstructured":"Darvin, P., Toor, S. M., Sasidharan Nair, V. & Elkord, E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp. Mol. Med. 50, 1\u201311 (2018).","journal-title":"Exp. Mol. Med."},{"key":"56537_CR7","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/COC.0000000000000239","volume":"39","author":"EI Buchbinder","year":"2016","unstructured":"Buchbinder, E. I. & Desai, A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am. J. Clin. Oncol. 39, 98\u2013106 (2016).","journal-title":"Am. J. Clin. Oncol."},{"key":"56537_CR8","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s13046-021-01987-7","volume":"40","author":"H Zhang","year":"2021","unstructured":"Zhang, H. et al. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer. J. Exp. Clin. Cancer Res. 40, 184 (2021).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"56537_CR9","doi-asserted-by":"publisher","first-page":"S1402","DOI":"10.1016\/j.annonc.2022.08.033","volume":"33","author":"S Qin","year":"2022","unstructured":"Qin, S. et al. LBA36 Final analysis of RATIONALE-301: Randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma. Ann. Oncol. 33, S1402\u2013S1403 (2022).","journal-title":"Ann. Oncol."},{"key":"56537_CR10","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","volume":"22","author":"Z Ren","year":"2021","unstructured":"Ren, Z. et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study. Lancet Oncol. 22, 977\u2013990 (2021).","journal-title":"Lancet Oncol."},{"key":"56537_CR11","doi-asserted-by":"publisher","first-page":"896752","DOI":"10.3389\/fimmu.2022.896752","volume":"13","author":"Y Chen","year":"2022","unstructured":"Chen, Y., Hu, H., Yuan, X., Fan, X. & Zhang, C. Advances in immune checkpoint inhibitors for advanced hepatocellular carcinoma. Front. Immunol. 13, 896752 (2022).","journal-title":"Front. Immunol."},{"key":"56537_CR12","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","volume":"76","author":"A-L Cheng","year":"2022","unstructured":"Cheng, A.-L. et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J. Hepatol. 76, 862\u2013873 (2022).","journal-title":"J. Hepatol."},{"key":"56537_CR13","doi-asserted-by":"crossref","unstructured":"Galle, P. R. et al. Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): first results from CheckMate 9DW. J. Clin. Oncol. 42, LBA4008 (2024).","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA4008"},{"key":"56537_CR14","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100070","volume":"1","author":"GK Abou-Alfa","year":"2022","unstructured":"Abou-Alfa, G. K. et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 1, EVIDoa2100070 (2022).","journal-title":"NEJM Evid."},{"key":"56537_CR15","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S1470-2045(23)00469-2","volume":"24","author":"JM Llovet","year":"2023","unstructured":"Llovet, J. M. et al. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial. Lancet Oncol. 24, 1399\u20131410 (2023).","journal-title":"Lancet Oncol."},{"key":"56537_CR16","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.annonc.2024.02.005","volume":"35","author":"B Sangro","year":"2024","unstructured":"Sangro, B. et al. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 35, 448\u2013457 (2024).","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"56537_CR17","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.3389\/fimmu.2020.01956","volume":"11","author":"Y Song","year":"2020","unstructured":"Song, Y. et al. Anti-angiogenic agents in combination with immune checkpoint inhibitors: a promising strategy for cancer treatment. Front. Immunol. 11, 1956 (2020).","journal-title":"Front. Immunol."},{"key":"56537_CR18","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2147\/JHC.S224938","volume":"7","author":"AL Raybould","year":"2020","unstructured":"Raybould, A. L. & Sanoff, H. Combination antiangiogenic and immunotherapy for advanced hepatocellular carcinoma: evidence to date. J. Hepatocell. Carcinoma 7, 133\u2013142 (2020).","journal-title":"J. Hepatocell. Carcinoma"},{"key":"56537_CR19","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3390\/livers3010011","volume":"3","author":"BF Far","year":"2023","unstructured":"Far, B. F. et al. Unresectable hepatocellular carcinoma: a review of new advances with focus on targeted therapy and immunotherapy. Livers 3, 121\u2013160 (2023).","journal-title":"Livers"},{"key":"56537_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202102500","volume":"8","author":"C Jiang","year":"2021","unstructured":"Jiang, C. et al. Engineering a smart agent for enhanced immunotherapy effect by simultaneously blocking PD-L1 and CTLA-4. Adv. Sci. 8, e2102500 (2021).","journal-title":"Adv. Sci."},{"key":"56537_CR21","doi-asserted-by":"crossref","unstructured":"Ma, Y. et al. Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors. J. Immunother. Cancer 11, e006654 (2023).","DOI":"10.1136\/jitc-2022-006654"},{"key":"56537_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45160-y","volume":"15","author":"Q Li","year":"2024","unstructured":"Li, Q. et al. The anti-PD-L1\/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial. Nat. Commun. 15, 1015 (2024).","journal-title":"Nat. Commun."},{"key":"56537_CR23","doi-asserted-by":"publisher","first-page":"262","DOI":"10.17998\/jlc.2023.07.17","volume":"23","author":"MMP Lee","year":"2023","unstructured":"Lee, M. M. P., Chan, L. L. & Chan, S. L. The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma. J. Liver Cancer 23, 262\u2013271 (2023).","journal-title":"J. Liver Cancer"},{"key":"56537_CR24","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1038\/s41591-024-03007-5","volume":"30","author":"X Gao","year":"2024","unstructured":"Gao, X. et al. Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b\/2 COMPASSION-04 trial. Nat. Med. 30, 1943\u20131951 (2024).","journal-title":"Nat. Med."},{"key":"56537_CR25","doi-asserted-by":"publisher","first-page":"S822","DOI":"10.1016\/j.annonc.2021.08.158","volume":"32","author":"B Xing","year":"2021","unstructured":"Xing, B. 938P KN046 (an anti-PD-L1\/CTLA-4 bispecific antibody) in combination with lenvatinib in the treatment for advanced unresectable or metastatic hepatocellular carcinoma (HCC): preliminary efficacy and safety results of a prospective phase II trial. Ann. Oncol. 32, S822 (2021).","journal-title":"Ann. Oncol."},{"key":"56537_CR26","doi-asserted-by":"crossref","unstructured":"Kopystecka, A., Patryn, R., Le\u015bniewska, M., Budzy\u0144ska, J. & Kozio\u0142, I. The use of ctDNA in the diagnosis and monitoring of hepatocellular carcinoma-literature review. Int. J. Mol. Sci. 24, 9342 (2023).","DOI":"10.3390\/ijms24119342"},{"key":"56537_CR27","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.3389\/fonc.2020.01290","volume":"10","author":"R Bai","year":"2020","unstructured":"Bai, R. et al. Mechanisms of cancer resistance to immunotherapy. Front. Oncol. 10, 1290 (2020).","journal-title":"Front. Oncol."},{"key":"56537_CR28","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/1754-9485.13405","volume":"66","author":"J Tibballs","year":"2022","unstructured":"Tibballs, J. & Clements, W. Immunotherapy and Transarterial therapy of HCC: what the interventional radiologist needs to know about the changing landscape of HCC treatment? J. Med. Imaging Radiat. Oncol. 66, 478\u2013482 (2022).","journal-title":"J. Med. Imaging Radiat. Oncol."},{"key":"56537_CR29","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.21037\/qims-20-173","volume":"11","author":"T Fang","year":"2021","unstructured":"Fang, T. et al. Combined with interventional therapy, immunotherapy can create a new outlook for tumor treatment. Quant. Imaging Med. Surg. 11, 2837\u20132860 (2021).","journal-title":"Quant. Imaging Med. Surg."},{"key":"56537_CR30","doi-asserted-by":"publisher","first-page":"93","DOI":"10.17998\/jlc.2022.03.28","volume":"22","author":"DH Kim","year":"2022","unstructured":"Kim, D. H. Combination of interventional oncology local therapies and immunotherapy for the treatment of hepatocellular carcinoma. J. Liver Cancer 22, 93\u2013102 (2022).","journal-title":"J. Liver Cancer"},{"key":"56537_CR31","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","volume":"22","author":"L Paz-Ares","year":"2021","unstructured":"Paz-Ares, L. et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 22, 198\u2013211 (2021).","journal-title":"Lancet Oncol."},{"key":"56537_CR32","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin, J. et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 381, 1535\u20131546 (2019).","journal-title":"N. Engl. J. Med."},{"key":"56537_CR33","doi-asserted-by":"publisher","first-page":"e204564","DOI":"10.1001\/jamaoncol.2020.4564","volume":"6","author":"T Yau","year":"2020","unstructured":"Yau, T. et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial. JAMA Oncol. 6, e204564 (2020).","journal-title":"JAMA Oncol."},{"key":"56537_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000496277","volume":"8","author":"M Kudo","year":"2019","unstructured":"Kudo, M. Combination cancer immunotherapy with molecular targeted agents\/anti-CTLA-4 antibody for hepatocellular carcinoma. Liver Cancer 8, 1\u201311 (2019).","journal-title":"Liver Cancer"},{"key":"56537_CR35","doi-asserted-by":"crossref","unstructured":"Kelley, R. K. et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. The Lancet. Oncology 23, 995\u20131008 (2022).","DOI":"10.1016\/S1470-2045(22)00326-6"},{"key":"56537_CR36","doi-asserted-by":"publisher","first-page":"S1401","DOI":"10.1016\/j.annonc.2022.08.032","volume":"33","author":"S Qin","year":"2022","unstructured":"Qin, S. et al. LBA35 Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): a randomized, phase III trial. Ann. Oncol. 33, S1401\u2013S1402 (2022).","journal-title":"Ann. Oncol."},{"key":"56537_CR37","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1007\/s12072-013-9481-9","volume":"7","author":"M Piciocchi","year":"2013","unstructured":"Piciocchi, M. et al. Circulating free DNA in the progression of liver damage to hepatocellular carcinoma. Hepatol. Int. 7, 1050\u20131057 (2013).","journal-title":"Hepatol. Int."},{"key":"56537_CR38","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1038\/nmat4997","volume":"16","author":"RH Xu","year":"2017","unstructured":"Xu, R. H. et al. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nat. Mater. 16, 1155\u20131161 (2017).","journal-title":"Nat. Mater."},{"key":"56537_CR39","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1158\/2159-8290.CD-20-0047","volume":"10","author":"Q Zhang","year":"2020","unstructured":"Zhang, Q. et al. Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade. Cancer Discov. 10, 1842\u20131853 (2020).","journal-title":"Cancer Discov."},{"key":"56537_CR40","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1158\/2159-8290.CD-17-0261","volume":"7","author":"J Goodall","year":"2017","unstructured":"Goodall, J. et al. Circulating cell-free DNA to guide prostate cancer treatment with PARP inhibition. Cancer Discov. 7, 1006\u20131017 (2017).","journal-title":"Cancer Discov."},{"key":"56537_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01590-0","volume":"21","author":"Y Yang","year":"2022","unstructured":"Yang, Y. et al. The clinical utility of dynamic ctDNA monitoring in inoperable localized NSCLC patients. Mol. Cancer 21, 117 (2022).","journal-title":"Mol. Cancer"},{"key":"56537_CR42","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo, M. et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391, 1163\u20131173 (2018).","journal-title":"Lancet"},{"key":"56537_CR43","doi-asserted-by":"crossref","unstructured":"Xing, B. et al. A phase II study combining KN046 (an anti-PD-L1\/CTLA-4 bispecific antibody) and lenvatinib in the treatment for advanced unresectable or metastatic hepatocellular carcinoma (HCC): Updated efficacy and safety results. J. Clin. Oncol. 40, 4115 (2022).","DOI":"10.1200\/JCO.2022.40.16_suppl.4115"},{"key":"56537_CR44","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.blre.2018.02.004","volume":"32","author":"A Thakur","year":"2018","unstructured":"Thakur, A., Huang, M. & Lum, L. G. Bispecific antibody based therapeutics: strengths and challenges. Blood Rev. 32, 339\u2013347 (2018).","journal-title":"Blood Rev."},{"key":"56537_CR45","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1080\/08923973.2023.2215404","volume":"45","author":"W Yang","year":"2023","unstructured":"Yang, W. et al. Efficacy and safety of immune checkpoint inhibitors combined with anti-VEGF therapy in the treatment of unresectable or advanced liver cancer: a systematic review. Immunopharmacol. Immunotoxicol. 45, 770\u2013779 (2023).","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"56537_CR46","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1002\/hep.32201","volume":"75","author":"Y Kurebayashi","year":"2022","unstructured":"Kurebayashi, Y. et al. Immunovascular classification of HCC reflects reciprocal interaction between immune and angiogenic tumor microenvironments. Hepatology 75, 1139\u20131153 (2022).","journal-title":"Hepatology"},{"key":"56537_CR47","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1101\/gr.129684.111","volume":"22","author":"DC Koboldt","year":"2012","unstructured":"Koboldt, D. C. et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 22, 568\u2013576 (2012).","journal-title":"Genome Res."},{"key":"56537_CR48","doi-asserted-by":"publisher","first-page":"i333","DOI":"10.1093\/bioinformatics\/bts378","volume":"28","author":"T Rausch","year":"2012","unstructured":"Rausch, T. et al. DELLY: structural variant discovery by integrated paired-end and split-read analysis. Bioinformatics 28, i333\u2013i339 (2012).","journal-title":"Bioinformatics"},{"key":"56537_CR49","doi-asserted-by":"publisher","first-page":"e1004873","DOI":"10.1371\/journal.pcbi.1004873","volume":"12","author":"E Talevich","year":"2016","unstructured":"Talevich, E., Shain, A. H., Botton, T. & Bastian, B. C. CNVkit: genome-wide copy number detection and visualization from targeted DNA sequencing. PLoS Comput. Biol. 12, e1004873 (2016).","journal-title":"PLoS Comput. Biol."},{"key":"56537_CR50","doi-asserted-by":"publisher","first-page":"5015","DOI":"10.1158\/1078-0432.CCR-19-0585","volume":"25","author":"W Fang","year":"2019","unstructured":"Fang, W. et al. Comprehensive genomic profiling identifies novel genetic predictors of response to anti-PD-(L)1 therapies in non-small cell lung cancer. Clin. Cancer Res. 25, 5015\u20135026 (2019).","journal-title":"Clin. Cancer Res."},{"key":"56537_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27022-z","volume":"12","author":"B Qiu","year":"2021","unstructured":"Qiu, B. et al. Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC. Nat. Commun. 12, 6770 (2021).","journal-title":"Nat. Commun."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-56537-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-56537-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-56537-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T11:48:13Z","timestamp":1738928893000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-56537-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,7]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["56537"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-56537-y","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,7]]},"assertion":[{"value":"29 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.W. and J.P. are employees of Nanjing Geneseeq Technology, Inc. T.X. is an employee of Jiangsu Alphamab Biopharmaceuticals Co., Ltd. The remaining authors declared that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1443"}}